On Monday, October 24, there will be a meeting of the Transparency Council. AOTMiT publishes the update.
The agenda includes:
Preparation of an opinion on the introduction of a comprehensive change in the current description of the drug program B.54. "Treatment of multiple myeloma patients (ICD-10: C90.0)."
Preparation of an opinion on reimbursement of drugs containing active substances:
- octreotide in the indications: pituitary gland (a tumor of ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
